Phase-Ib/IIa study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of orally inhaled multiple doses of POL6014 in patients with Cystic Fibrosis
Phase of Trial: Phase I/II
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs POL 6014 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Santhera Pharmaceuticals
- 24 Oct 2018 According to a Santhera Pharmaceuticals media release, the Cystic Fibrosis Foundation (CFF) is providing funding support for the conduct of the safety trials with POL6014.
- 24 Oct 2018 According to a Santhera Pharmaceuticals media release, this trial is expected to complete in 2H 2019.
- 19 Jun 2018 Status changed from planning to recruiting.